DashboardPortfoliosWatchlistCommunityDiscoverScreener
NOT FOR DISTRIBUTION

1CM Inc.

CNSX:EPIC Stock Report

Market Cap: CA$35.3m

  • Company Overview
  • Valuation
  • Future Growth
  • Past Performance
  • Financial Health
  • Dividend
  • Management
  • Ownership
  • Other Information
  • Stock Community

1CM Past Earnings Performance

Past criteria checks 3/6

1CM has been growing earnings at an average annual rate of 68%, while the Pharmaceuticals industry saw earnings growing at 27.1% annually. Revenues have been growing at an average rate of 51.5% per year. 1CM's return on equity is 14%, and it has net margins of 6.3%.

Key information

68.03%

Earnings growth rate

69.36%

EPS growth rate

Pharmaceuticals Industry Growth23.06%
Revenue growth rate51.52%
Return on equity13.97%
Net Margin6.30%
Last Earnings Update31 May 2026

Recent past performance updates

Analysis Article • May 07

1CM's (CSE:EPIC) Earnings Are Of Questionable Quality

Despite posting some strong earnings, the market for 1CM Inc.'s ( CSE:EPIC ) stock hasn't moved much. Our analysis...

Recent updates

Analysis Article • May 07

1CM's (CSE:EPIC) Earnings Are Of Questionable Quality

Despite posting some strong earnings, the market for 1CM Inc.'s ( CSE:EPIC ) stock hasn't moved much. Our analysis...
Analysis Article • Dec 12

Positive Sentiment Still Eludes 1CM Inc. (CSE:EPIC) Following 56% Share Price Slump

The 1CM Inc. ( CSE:EPIC ) share price has fared very poorly over the last month, falling by a substantial 56%. The drop...
Analysis Article • Oct 28

A Piece Of The Puzzle Missing From 1CM Inc.'s (CSE:EPIC) 86% Share Price Climb

The 1CM Inc. ( CSE:EPIC ) share price has done very well over the last month, posting an excellent gain of 86%. Looking...
Analysis Article • Sep 10

The Market Lifts 1CM Inc. (CSE:EPIC) Shares 44% But It Can Do More

Despite an already strong run, 1CM Inc. ( CSE:EPIC ) shares have been powering on, with a gain of 44% in the last...
Analysis Article • Jul 08

Not Many Are Piling Into 1CM Inc. (CSE:EPIC) Just Yet

There wouldn't be many who think 1CM Inc.'s ( CSE:EPIC ) price-to-sales (or "P/S") ratio of 0.4x is worth a mention...
Analysis Article • Apr 04

Investors Give 1CM Inc. (CSE:EPIC) Shares A 48% Hiding

1CM Inc. ( CSE:EPIC ) shareholders won't be pleased to see that the share price has had a very rough month, dropping...
Analysis Article • Nov 27

Even With A 135% Surge, Cautious Investors Are Not Rewarding 1CM Inc.'s (CSE:EPIC) Performance Completely

1CM Inc. ( CSE:EPIC ) shareholders would be excited to see that the share price has had a great month, posting a 135...
Analysis Article • Sep 29

1CM Inc. (CSE:EPIC) Might Not Be As Mispriced As It Looks After Plunging 30%

To the annoyance of some shareholders, 1CM Inc. ( CSE:EPIC ) shares are down a considerable 30% in the last month...
Analysis Article • Aug 15

1CM Inc. (CSE:EPIC) Stock's 32% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Unfortunately for some shareholders, the 1CM Inc. ( CSE:EPIC ) share price has dived 32% in the last thirty days...
Analysis Article • Jun 16

Not Many Are Piling Into 1CM Inc. (CSE:EPIC) Stock Yet As It Plummets 32%

Unfortunately for some shareholders, the 1CM Inc. ( CSE:EPIC ) share price has dived 32% in the last thirty days...
Analysis Article • Apr 27

Why We're Not Concerned Yet About 1CM Inc.'s (CSE:EPIC) 33% Share Price Plunge

1CM Inc. ( CSE:EPIC ) shares have had a horrible month, losing 33% after a relatively good period beforehand. The drop...
Analysis Article • Feb 07

What You Can Learn From 1CM Inc.'s (CSE:EPIC) P/S

When close to half the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or "P/S") below...
Analysis Article • Jun 27

Investors Appear Satisfied With 1CM Inc.'s (CSE:EPIC) Prospects

1CM Inc.'s ( CSE:EPIC ) price-to-sales (or "P/S") ratio of 12.6x may look like a poor investment opportunity when you...

Revenue & Expenses Breakdown

How 1CM makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CNSX:EPIC Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 May 26755130
28 Feb 26754130
30 Nov 25751130
31 Aug 25730120
31 May 25702100
28 Feb 2567290
30 Nov 2462190
31 Aug 2457180
31 May 2452-180
29 Feb 2446-180
30 Nov 2340-270
31 Aug 2335-170
31 May 2324-270
28 Feb 2315-360
30 Nov 228-340
31 Aug 221-530
31 May 221-540
28 Feb 221-550
30 Nov 211-540
31 Aug 210-540
31 May 210-420
28 Feb 210-310
30 Nov 200-310
31 Aug 200-310
31 May 200-2810
29 Feb 200-2810
30 Nov 190-2810
31 Aug 190-2910
31 May 190-750
28 Feb 190-860
30 Nov 180-760
31 Aug 180-660
31 May 180-220
28 Feb 180000
30 Nov 170000
31 Aug 170000
31 May 170000
28 Feb 170000
30 Nov 160000
31 Aug 160000
31 May 160-100
29 Feb 160-100

Quality Earnings: EPIC has a large one-off gain of CA$4.1M impacting its last 12 months of financial results to 31st May, 2026.

Growing Profit Margin: EPIC's current net profit margins (6.3%) are higher than last year (2.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EPIC has become profitable over the past 5 years, growing earnings by 68% per year.

Accelerating Growth: EPIC's earnings growth over the past year (172.5%) exceeds its 5-year average (68% per year).

Earnings vs Industry: EPIC earnings growth over the past year (172.5%) did not outperform the Pharmaceuticals industry 225.5%.


Return on Equity

High ROE: EPIC's Return on Equity (14%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 23:05
End of Day Share Price 2026/09/10 00:00
Earnings2026/05/31
Annual Earnings2025/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
  • SEC Form 10-K
  • SEC Form 10-Q
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
  • Analyst Research Reports
  • Blue Matrix
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
  • ICE Market Data
  • SEC Form S-1
Ownership10 years
  • Top shareholders
  • Insider trading
  • SEC Form 4
  • SEC Form 13D
Management10 years
  • Leadership team
  • Board of directors
  • SEC Form 10-K
  • SEC Form DEF 14A
Key Developments10 years
  • Company announcements
  • SEC Form 8-K

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

1CM Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide